Finasteride for chronic central serous chorioretinopathy.
Finasteride for chronic central serous chorioretinopathy.
复制标题
DOI：
10.1097/iae.0b013e3181f04a35
复制
发表时间：
2011-04
期刊：
影响因子：
--
通讯作者：
Meyerle CB
中科院分区：
文献类型：
--
作者：
Forooghian F;Meleth AD;Cukras C;Chew EY;Wong WT;Meyerle CB
评价二羟睾酮（DHT）合成抑制剂非那肽治疗慢性中心性浆液性脉络膜视网膜病变（CSC）的安全性和有效性。5例慢性CSC患者前瞻性入组本初步研究。患者每天接受非那肽（5 mg）给药，持续3个月，之后停用研究药物，并观察患者3个月。主要结果指标包括最佳矫正视力（BCVA），中心子场黄斑厚度和视网膜下液量（通过光学相干断层扫描（OCT）评估）。同时测定血清二氢睾酮、血清睾酮和尿皮质醇。平均BCVA无变化。平均中心-子场黄斑厚度和视网膜下液量在3个月时达到最低点，并在6个月时上升至低于基线的水平。OCT参数的变化与血清DHT水平的变化一致。在4例患者中，停用芬布地后，中心子场黄斑厚度和/或视网膜下液量增加。在其余患者中，两个OCT参数均在使用非那普利后恢复正常，并在停用研究药物后保持稳定。芬必得可能是慢性CSC的一种新的药物治疗。需要更大规模的对照临床试验来进一步评估芬鲁肽治疗CSC的疗效。初步研究，以评估finlavide治疗慢性中心性浆液性脉络膜视网膜病变的疗效和耐受性。
To evaluate the safety and efficacy of finasteride, an inhibitor of dihyroxytestosterone (DHT) synthesis, in the treatment of chronic central serous chorioretinopathy (CSC). Five patients with chronic CSC were prospectively enrolled in this pilot study. Patients were administered finasteride (5mg) daily for 3 months, following which study medication was withheld and patients were observed for 3 months. Main outcome measures included best-corrected visual acuity (BCVA), center-subfield macular thickness and subretinal fluid volume as assessed by optical coherence tomography (OCT). Serum DHT, serum testosterone, and urinary cortisol were also measured. There was no change in mean BCVA. Mean center-subfield macular thickness and subretinal fluid volume reached a nadir at 3 months, and rose to levels that were below baseline by 6 months. The changes in both OCT parameters paralleled changes in serum DHT level. In four patients, center-subfield macular thickness and/or subretinal fluid volume increased following discontinuation of finasteride. In the remaining patient, both OCT parameters normalized with finasteride and remained stable when the study medication was discontinued. Finasteride may represent a novel medical treatment for chronic CSC. Larger controlled clinical trials are needed to further assess the efficacy of finasteride for the treatment of CSC. Pilot study to evaluate finasteride for treatment of chronic central serous chorioretinopathy suggests efficacy and tolerability.